Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.52 |
| ▸ | ESR1 | P03372 | 6/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25804086 | 0.85 | HSD17B1 (0.56) | MCL1HSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL28740702 | 0.85 | MCL1 (0.65) | MCL1CNR1CNR2ALOX5CYP17A1 | |
| SCHEMBL332894 | 0.84 | CNR1 (0.67) | MCL1CNR1CNR2ESR2ESR1 | |
| SCHEMBL2862161 | 0.82 | ESR2 (0.69) | HSD17B1HSD17B2ESR2ESR1HCAR2 | |
| Propane SCHEMBL17699241 | 0.82 | HSD17B1 (0.61) | HSD17B1HSD17B2ESR2ESR1AR | |
| SCHEMBL13589555 | 0.82 | HSD17B1 (0.72) | MCL1HSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL3811825 | 0.82 | HSD17B1 (0.72) | MCL1HSD17B1HSD17B2ESR2ESR1 | |
| SCHEMBL24411254 | 0.81 | MCL1 (0.44) | MCL1CNR1CNR2HSD17B1HSD17B2 | |
| SCHEMBL10435290 | 0.80 | MCL1 (0.59) | MCL1CNR1CNR2HSD17B1HSD17B2 | |
| SCHEMBL29696046 | 0.79 | HSD17B1 (0.68) | MCL1HSD17B1HSD17B2ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7785675-B2 | Compound and liquid crystal composition | ADEKA CORPORATION (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7785675-B2 | Compound and liquid crystal composition | ADEKA CORPORATION (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7785675-B2 | Compound and liquid crystal composition | ADEKA CORPORATION (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090103041-A1 | Novel compound and liquid crystal composition | ADEKA CORPORATION (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090103041-A1 | Novel compound and liquid crystal composition | ADEKA CORPORATION (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090103041-A1 | Novel compound and liquid crystal composition | ADEKA CORPORATION (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090103041-A1 | Novel compound and liquid crystal composition | PYM1, H1-0, H1-2 | MCL1 496/4885CNR1 115/4885CNR2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.